AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00555412
Drug: D - inhaled placebo q 4 h x 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo aerosol inhalation (0 mg total)
Trial: NCT02497716
Drug: Rivaroxaban (Xarelto, BAY59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of reconstituted rivaroxaban granules
Trial: NCT01169103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
Trial: NCT00217841
Drug: Aurograb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03061227
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized application of glucagon or saline during oral glucose tolerance test
Trial: NCT02531113
Drug: RPC1063
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01582815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
Trial: NCT01040494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
Trial: NCT04622111
Drug: CPL207280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
Trial: NCT04622111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT04072926
Drug: BioRoot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influence of biomaterial BioRoot on periapical healing
Trial: NCT04472611
Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin
RxNorm normalized name: colchicine and probenecid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
Trial: NCT03494946
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: May include chemotherapy, TACE, SIRT or other available treatment options.
Trial: NCT02531152
Drug: SAR366234
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00648011
Drug: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
RxNorm normalized name: hydrochlorothiazide / quinapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fed
Trial: NCT00648011
Drug: Accuretic™ Tablets 20 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fed
Trial: NCT02246049
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03662958
Drug: Lutrate
RxNorm normalized name: Lutrate Depot 3-Month 22.5mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a novel leuprolide acetate 3.75mg depot
Trial: NCT00303823
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00010400
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01512199
Drug: U3-1287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U3-1287: 18 mg/kg administered intravenously once every three weeks
Trial: NCT01512199
Drug: U3-1287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
Trial: NCT01512199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
Trial: NCT02343042
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT01003158
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Oral bid
Trial: NCT00325715
Drug: AGN 201904
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01733875
Drug: CC-220 0.03 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of CC-220 0.03 mg will be administered orally once a day.
Trial: NCT01733875
Drug: CC-220 0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of CC-220 0.1 mg will be administered orally once a day.
Trial: NCT01733875
Drug: CC-220 0.3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of CC-220 0.3 mg will be administered orally once a day.
Trial: NCT02300844
Drug: NNC0174-0833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated.
Trial: NCT02300844
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
Trial: NCT01733875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo will be administered orally once a day.
Trial: NCT01116180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule matching the active comparator. Given for 7 days once daily.
Trial: NCT02201043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01555099
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhaled
Trial: NCT01555099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhaled
Trial: NCT00003868
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003868
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00955825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
Trial: NCT00478595
Drug: Placebo (for Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT00478595
Drug: Anti-diabetic monotherapy
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
Trial: NCT03282461
Drug: ABY-029
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
Trial: NCT04950933
Drug: Huolingshengji Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
Trial: NCT00537602
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04291846
Drug: SHR1459 fasted in P1, high-fat diet in P2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
Trial: NCT04291846
Drug: SHR1459 high-fat diet in P1, fasted in P2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
Trial: NCT00469040
Drug: GW642444M for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M salt
Trial: NCT00391846
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00391846
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00391846
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00391846
Drug: HF treatment according to Swedish guidelines
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03394196
Drug: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
Trial: NCT03394196
Drug: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
Trial: NCT02914639
Drug: SF0166 Topical Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01960140
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01904071
Drug: IVMS (IV Morphine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Morphine
Trial: NCT02819414
Drug: Paracetamol drops
RxNorm normalized name: Soul Pattinson Colour Free Paracetamol Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
Trial: NCT00818454
Drug: Combivent CFC MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00818454
Drug: Respimat Combivent
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01867216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules
Trial: NCT01867216
Drug: LY2922470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules
Trial: NCT00693121
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
Trial: NCT04050644
Drug: Preservative Free drop treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
Trial: NCT04050644
Drug: Preserved drop treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
Trial: NCT01443845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo, oral administration, once per day.
Trial: NCT00561301
Drug: GemDOx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine oxliplatin
Trial: NCT03381703
Drug: YH12852
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH12852 administration
Trial: NCT02271854
Drug: Diclofenac sodium gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Trial: NCT02271854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Trial: NCT00807144
Drug: Kidney transplant maintenance immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
Trial: NCT00735072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
Trial: NCT03923829
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: systemic administration of Zinc sulfate with scaling and root planing
Trial: NCT03454529
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01456013
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for patients at risk of CIN
Trial: NCT03465527
Drug: PrednisoLONE 50 MG
RxNorm normalized name: prednisolone 50 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
Trial: NCT02086097
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25m of dexketoprofen (oral intake) every 8 hours
Trial: NCT02086097
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg of Ibuprofen (Oral Intake) every 8 hours
Trial: NCT02086097
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INACTIVE SUGAR PILLS
Trial: NCT00240149
Drug: Regular Insulin via Insulin-Glucose Algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02568644
Drug: Intravenous ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
Trial: NCT00404573
Drug: RGH-188
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00729560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 4 weeks
Trial: NCT01511549
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Trial: NCT01511549
Drug: SAR113945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Trial: NCT00634075
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
Trial: NCT01972724
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea as prescribed in clinical practice
Trial: NCT01721434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar coloured placebo
Trial: NCT03186079
Drug: Fiberform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
Trial: NCT01408732
Drug: Sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
Trial: NCT00749749
Drug: ON-Q PainBuster Post-op Pain relief System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
Trial: NCT00002919
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002919
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01897259
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
Trial: NCT01897259
Drug: Corticosteroid Injections
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
Trial: NCT03598140
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once (Group 1) or daily for 2 weeks (Group 2)
Trial: NCT01845428
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
Trial: NCT00648349
Drug: Aciphex® Delayed-Release Tablets 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fasting
Trial: NCT00681525
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One ABT-335 135 mg capsule QD for 10 days
Trial: NCT02658240
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg epinephrine
Trial: NCT02918279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily subcutaneously (s.c., under the skin)
Trial: NCT03860532
Drug: HMPL-011 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
Trial: NCT03860532
Drug: HMPL-011 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
Trial: NCT02432690
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
Trial: NCT00875160
Drug: AT2101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
Trial: NCT04688801
Drug: Chemotherapy Drugs, Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy± Radiotherapy after surgery
Trial: NCT01135511
Drug: CP-690,550 Eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
Trial: NCT04432324
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT
Trial: NCT04679571
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year.
Trial: NCT01641224
Drug: Ledebouriella Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledebouriella Root (\~10g)
Trial: NCT03583125
Drug: EOC317
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet(s) PO
Trial: NCT01641224
Drug: Fingered citron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingered citron (\~10g)
Trial: NCT01641224
Drug: Tuckahoe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuckahoe (15g)
Trial: NCT01641224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is blindly given to patients.
Trial: NCT02329860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no